Ypsomed grows strongly in pharma customer business and continues to invest in the market development of the insulin pump

Press Releases Ypsomed Group

Burgdorf – In the financial year 2019/20, Ypsomed achieved consolidated sales of CHF 393.9 million (previous year: CHF 453.8 million). In the previous year, Ypsomed generated a turnover of 352.8 million in continuing operations. On this comparative basis, the result represents growth of CHF 41.0 million or 11.6 %. The operating result (EBIT) amounts to CHF 9.3 million. In the previous year, the discontinued operation contributed with CHF 61.9 million to the operating result of CHF 73.3 million. Net profit amounts to CHF 11.5 million (previous year: CHF 60.1 million).

Ypsomed and Dexcom enter into partnership to drive closed loop system.

Press Releases Ypsomed Group

Burgdorf/San Diego – Ypsomed (SWX:YPSN) and DexCom Inc. (NASDAQ:DXCM), the world's leading provider of continuous glucose monitoring (CGM) systems, announce their partnership to drive development of a hybrid closed loop system. The partnership is an important milestone in the further development of individualised diabetes therapy. In a first step, CGM data from Dexcom will be integrated into the mylife App from Ypsomed.

Ypsomed grows strongly in the pen business

Press Releases Ypsomed Group

Burgdorf – Ypsomed achieved a consolidated total turnover of CHF 190.6 million during the first half-year of the business year 2019/20. EBIT from continuing operations increased by 71 %, the Ypsomed Delivery Systems segment grew by 33.8 %. The half-year results show that the platform strategy for pens and autoinjectors is paying off.

Ypsomed expands headquarters in Burgdorf

Press Releases Ypsomed Group

Burgdorf – Ypsomed opens its new and renovated buildings at the headquarters in Burgdorf. With this expansion, Ypsomed secures the additional capacities and workplaces it needs to continue growing in the future.

Ypsomed opens production plant in Schwerin, Germany

Press Releases Ypsomed Group

Burgdorf – Ypsomed opens its new production plant in Schwerin, in north-eastern Germany. Ypsomed is thus ensuring the necessary production capacities for growth in the coming years. Around 200 jobs will be created at the new production site over the next few years.